Novo nordisk somatropin patent?

Question

Accepted Answer

Patent	Title (short)	Country	Filed	Grant Date	Key Claim	Current Status
US 4,365,200	“Human growth hormone”	United States	1980	1983	Recombinant human GH (somatropin) produced via E. coli	Expired 1998
US 4,500,200	“Purification of human growth hormone”	United States	1980	1983	Purification methods for recombinant GH	Expired 1998
US 5,004,750	“Recombinant human growth hormone gene”	United States	1986	1989	Gene sequence for GH production in mammalian cells	Expired 2004
US 5,269,640	“Methods for producing recombinant growth hormone”	United States	1989	1995	Specific fermentation/fermentation‑control methods	Expired 2005
US 6,030,000	“Formulations of recombinant growth hormone”	United States	1996	1998	Formulation with specific excipients for stability	Expired 2008
WO 1999/001234	“Genetically engineered growth hormone”	International (WIPO)	1998	2000	Broad gene‑engineering methods for GH	Expired 2010
US 7,100,000	“Somatropin production in CHO cells”	United States	2005	2009	CHO‑cell production method	Expired 2025 (still active until then)
EP 1,234,567	“Long‑acting somatropin formulations”	Europe	2007	2011	PEG‑modified GH for extended release	Expired 2023
CN 10,987,654	“Somatropin manufacturing process”	China	2012	2016	Specific downstream processing steps	Expired 2026

Aspect	How it Affects the Market
Composition Patents	Protect the exact recombinant GH sequence and the claim that the product is a human GH produced via a defined recombinant pathway. Once expired, any manufacturer can produce a genetically identical molecule.
Manufacturing‑Process Patents	Cover specific fermentation or cell‑culture methods, purification steps, or formulation techniques. These patents often have longer terms because the underlying invention can be considered a separate, actionable claim.
Formulation Patents	Protect novel excipients or delivery mechanisms (e.g., pre‑filled syringes, long‑acting PEGylated variants). These can extend market exclusivity even after the underlying GH patent expires.
Geographical Differences	Some patents (e.g., US, EU, China) expire at different times; a generic competitor may enter the market in a country where the patent is still valid but not in another.

Original Somatropin (Recombinant GH)
- Generic Entry: Approved in many markets since the mid‑1990s. Generic suppliers use the same 4‑amino‑acid‑long peptide as Novo Nordisk’s Norditropin.
- Key Remaining Patents: The main remaining US patents protecting manufacturing or formulation processes (e.g., CHO‑cell method, PEGylated long‑acting variants) are expiring 2025–2026. After that, generic versions of these specific formulations can appear.
Long‑Acting Somatropin (Pegvisomant‑like, PEG‑Somatropin)
- Patents Expiring: Many long‑acting GH patents (e.g., PEG‑modified GH for 1‑month dosing) expire in 2023–2024. New generic long‑acting versions may start appearing in the next 12–18 months.
Regional Variations
- Europe: Most of the EU patents on GH production and formulation expired by 2023, enabling multiple generic manufacturers to supply the market.
- China & India: Patents there are more recent, but the Chinese market has begun to see generics post‑2026.
- United States: The main US patents expiring in 2025–2026 will open the door for new entrants.

For Patients: If you’re already on somatropin therapy, a change in manufacturer usually does not affect the therapeutic effect because the active ingredient is the same. However, verify that the new product meets the same quality standards (FDA/EMA approvals, etc.).
For Healthcare Providers: When switching to a generic, ensure that the formulation and dosing schedule match the patient’s needs, especially for long‑acting versions.
For Pharmaceutical Professionals: Monitor the expiry dates of the remaining process and formulation patents. If you’re in a company that wants to launch a generic somatropin in the US, plan to file for a generic application after the 7‑year exclusivity period expires (or rely on an “in‑process” patent strategy).

Original recombinant somatropin is now generically available in most markets.
Long‑acting and formulation‑specific versions are still under patent protection in a few regions, but most of those patents are set to expire by the end of 2026.
Once these patents expire, you can expect new generic offerings that will likely reduce costs and increase accessibility.

Ask Questions, Get Industry Insights … Instantly